SLNO Soleno Therapeutics Inc
Price (delayed)
$73.67
Market cap
$3.38B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.38
Enterprise value
$3.34B
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet
Highlights
SLNO's equity has surged by 56% year-on-year but it is down by 7% since the previous quarter
Soleno Therapeutics's quick ratio has decreased by 9% QoQ but it has increased by 5% YoY
The EPS has dropped by 86% year-on-year and by 62% since the previous quarter
Soleno Therapeutics's net income has decreased by 34% from the previous quarter
Key stats
What are the main financial stats of SLNO
Market
Valuations
Earnings
Shares outstanding
45.86M
Market cap
$3.38B
Enterprise value
$3.34B
Price to earnings (P/E)
N/A
Price to book (P/B)
12.96
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$184.43M
Net income
-$175.85M
EBIT
-$175.62M
EBITDA
-$173.19M
Free cash flow
-$69.31M
Per share
Balance sheet
Liquidity
EPS
-$4.38
EPS diluted
-$4.38
Free cash flow per share
-$1.73
Book value per share
$5.68
Revenue per share
$0
TBVPS
$8.07
Total assets
$330.97M
Total liabilities
$85.86M
Debt
$52.83M
Equity
$245.11M
Working capital
$275.14M
Debt to equity
0.22
Current ratio
15.68
Quick ratio
15.55
Net debt/EBITDA
0.2
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-63.9%
Return on equity
-75.3%
Return on invested capital
-84.2%
Return on capital employed
-56.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLNO stock price
How has the Soleno Therapeutics stock price performed over time
Intraday
7.93%
1 week
50.44%
1 month
50.9%
1 year
76.2%
YTD
63.89%
QTD
3.11%
Financial performance
How have Soleno Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$184.43M
Net income
-$175.85M
Gross margin
N/A
Net margin
N/A
Soleno Therapeutics's net income has decreased by 34% from the previous quarter
The operating income has contracted by 33% from the previous quarter
Growth
What is Soleno Therapeutics's growth rate over time
Valuation
What is Soleno Therapeutics stock price valuation
P/E
N/A
P/B
12.96
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 86% year-on-year and by 62% since the previous quarter
The price to book (P/B) is 167% higher than the 5-year quarterly average of 4.5 and 60% higher than the last 4 quarters average of 7.5
SLNO's equity has surged by 56% year-on-year but it is down by 7% since the previous quarter
Efficiency
How efficient is Soleno Therapeutics business performance
The company's return on assets fell by 21% YoY and by 16% QoQ
The ROE has contracted by 21% from the previous quarter but it has grown by 6% YoY
The return on invested capital rose by 11% since the previous quarter
Dividends
What is SLNO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLNO.
Financial health
How did Soleno Therapeutics financials performed over time
The total liabilities has soared by 168% QoQ
SLNO's total assets has soared by 83% year-on-year and by 12% since the previous quarter
SLNO's debt is 78% smaller than its equity
SLNO's equity has surged by 56% year-on-year but it is down by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.